Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 764198 in Subjects With Renal Impairment
NCT04176536Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apecotrep in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 96 hours and Maximum measured concentration of the analyte in plasma up to 96 hours. Started Dec 2019; status: completed.
02
Drugs
apecotrep
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04176536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176536.